Loading
What changed between revision 2 and revision 3, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 2
Import
Re-import of content/aubrey-de-grey.md — the file changed after the initial import. Not an edit.
11.8 kB
Revision 2
Revision 3
lines 7–13 → 7–136 unchanged lines not shown
categories: ["people", "longevity"]categories: ["people", "longevity"]tags: ["aging", "sens", "biogerontology", "life extension", "rejuvenation", "advocacy"]tags: ["aging", "sens", "biogerontology", "life extension", "rejuvenation", "advocacy"]summary: "British biogerontologist who proposed the SENS damage-repair framework for rejuvenation and popularized the idea of longevity escape velocity."summary: "British biogerontologist who proposed the SENS damage-repair framework for rejuvenation and popularized the idea of longevity escape velocity."updated: "2026-08-23"updated: "2026-10-29"------ ```infobox```infoboxlines 28–45 → 28–4514 unchanged lines not shown
**Aubrey de Grey** is a British biogerontologist who argues that aging should be treated as a**Aubrey de Grey** is a British biogerontologist who argues that aging should be treated as afinite set of accumulated molecular and cellular lesions that periodic repair can remove, ratherfinite set of accumulated molecular and cellular lesions that periodic repair can remove, ratherthan as a metabolic process that medicine must learn to slow. He formalized that position as SENSthan as a metabolic process that medicine must learn to slow. He formalized that position as SENS— Strategies for Engineered Negligible Senescence — and popularized the term(Strategies for Engineered Negligible Senescence) and popularized the term[[longevity-escape-velocity]]. He is the most visible advocate of radical life extension and among[[longevity-escape-velocity]]. He is the most visible advocate of radical life extension and amongthe most heavily criticized figures in the field.the most heavily criticized figures in the field. ## Overview## Overview De Grey's importance is organizational and rhetorical more than experimental. He has run almost noDe Grey's importance is organizational and rhetorical more than experimental. He has run almost nowet-lab research of his own, and his primary contribution is a framework: a claim that the damagewet-lab research of his own. His primary contribution is a framework, which claims that the damageaccumulated during aging falls into a small number of categories, that each category has aaccumulated during aging falls into a small number of categories, that each category has aconceivable repair strategy, and that the list is complete enough to serve as an engineeringconceivable repair strategy, and that the list is complete enough to serve as an engineeringspecification. Mainstream biogerontology has largely accepted his framing question — whether agingspecification. Mainstream biogerontology has largely accepted his framing question, whether aging isis tractable at all — while rejecting his timelines and much of his confidence.tractable at all, while rejecting his timelines and much of his confidence. ## Career## Career lines 55–70 → 55–699 unchanged lines not shown
[[sens-research-foundation]] in California, and later committed a substantial personal inheritance[[sens-research-foundation]] in California, and later committed a substantial personal inheritanceto it and to allied organizations. The foundation funded work on lysosomal enzymes forto it and to allied organizations. The foundation funded work on lysosomal enzymes for[[proteostasis|aggregate clearance]], allotopic expression of mitochondrial genes, and immune[[proteostasis|aggregate clearance]], allotopic expression of mitochondrial genes, and immuneapproaches to [[cellular-senescence|senescent cells]] — several years before [[senolytics]] becameapproaches to [[cellular-senescence|senescent cells]], several years before [[senolytics]] becamea mainstream target.a mainstream target. ## SENS and the damage-repair thesis## SENS and the damage-repair thesis The name is borrowed from comparative biology: a species showsThe name is borrowed from comparative biology: a species shows [[negligible-senescence]] when its[[negligible-senescence]] when its mortality rate does not rise measurably with age. SENSmortality rate does not rise measurably with age. SENS proposes to engineer that condition ratherproposes to engineer that condition rather than find it. It partitions age-related damage intothan find it. It partitions age-related damage into seven categories: cell loss and atrophy,seven categories: cell loss and atrophy, cancerouscancerous mutations, [[mitochondrial-dysfunction|mitochondrial DNA mutations]], death-resistant cells,mutations, [[mitochondrial-dysfunction|mitochondrial DNA mutations]], death-resistant cells,extracellular crosslinks, extracellular aggregates, and intracellular aggregates. For each, de Greyextracellular crosslinks, extracellular aggregates, and intracellular aggregates. For each, de Greyproposes a repair rather than a prevention: replace lost cells withproposes a repair rather than a prevention: replace lost cells with[[induced-pluripotent-stem-cells|stem-cell derivatives]], remove senescent cells, back up[[induced-pluripotent-stem-cells|stem-cell derivatives]], remove senescent cells, back uplines 73–81 → 72–802 unchanged lines not shown
> [!key] Why the framing matters> [!key] Why the framing matters> Damage repair is agnostic about the causes of aging. If the categories are complete, a therapy> Damage repair is agnostic about the causes of aging. If the categories are complete, a therapy> works even if nobody knows why the damage forms — the same logic by which a mechanic restores a> works even if nobody knows why the damage forms, in the way a mechanic restores a car without a> car without a theory of corrosion. The whole argument rests on completeness, which is exactly what> theory of corrosion. The whole argument rests on completeness, and completeness is what critics> critics dispute.> dispute. The scheme predates and partly overlaps the [[hallmarks-of-aging]] taxonomy published in 2013, andThe scheme predates and partly overlaps the [[hallmarks-of-aging]] taxonomy published in 2013, andthe two are often compared. The hallmarks are a consensus classification derived from experimentalthe two are often compared. The hallmarks are a consensus classification derived from experimentallines 88–97 → 87–966 unchanged lines not shown
treated person enough additional years for the next generation to arrive, remaining life expectancytreated person enough additional years for the next generation to arrive, remaining life expectancystops falling. He has repeatedly given roughly even odds of reaching that threshold within astops falling. He has repeatedly given roughly even odds of reaching that threshold within adecade or two, conditional on funding, and has said that the first person to live past 1,000 maydecade or two, conditional on funding, and has said that the first person to live past 1,000 mayalready be born — a claim that sits far outside anything the record ofalready be born. That claim sits far outside anything the record of[[maximum-human-lifespan|documented human longevity]] supports. No demographic or biological[[maximum-human-lifespan|documented human longevity]] supports. No demographic or biologicalevidence establishes a date, and de Grey presents these as conditional forecasts rather thanevidence establishes a date, and de Grey presents these as conditional forecasts rather thanprojections from data. The framing has the useful property of shifting attention fromprojections from data. One useful effect of the framing is that it shifts attention from[[healthspan|how long people stay well]] to the rate at which therapies improve.[[healthspan|how long people stay well]] to the rate at which therapies improve. ## Reception## Receptionlines 100–113 → 99–1122 unchanged lines not shown
any molecular biologist who could demonstrate that SENS was too wrong to merit debate. A panelany molecular biologist who could demonstrate that SENS was too wrong to merit debate. A panelincluding Craig Venter, Nathan Myhrvold and Rodney Brooks concluded in 2006 that no submission metincluding Craig Venter, Nathan Myhrvold and Rodney Brooks concluded in 2006 that no submission metthat bar, while also finding SENS highly speculative and largely unsupported by reproduciblethat bar, while also finding SENS highly speculative and largely unsupported by reproducibleresults; a critique led by Preston Estep received a partial award.[^tr2006] The verdict has beenresults; a critique led by Preston Estep received a partial award.[^tr2006] Both sides have citedcited by both sides ever since — as vindication that SENS is not pseudoscience, and as confirmationthe verdict ever since, one as vindication that SENS is not pseudoscience and the other asthat it is unproven.confirmation that it is unproven. A 2005 *EMBO Reports* commentary signed by a large group of biogerontologists, including StevenA 2005 *EMBO Reports* commentary signed by a large group of biogerontologists, including StevenAustad and Huber Warner, argued that none of the SENS proposals had been shown to work in a mammalAustad and Huber Warner, argued that none of the SENS proposals had been shown to work in a mammaland that presenting them as a near-term engineering plan misrepresented the state of theand that presenting them as a near-term engineering plan misrepresented the state of thescience.[^warner2005] That remains the mainstream position: the categories are a useful checklist,science.[^warner2005] That remains the mainstream position. The categories are a useful checklist,the timelines are not credible, and the gap between a mouse result and a human therapy isthe timelines are not credible, and the gap between a mouse result and a human therapy issystematically understated.systematically understated. lines 134–153 → 133–15120 unchanged lines not shown
Since late 2022 de Grey has led the Longevity Escape Velocity Foundation, announced at theSince late 2022 de Grey has led the Longevity Escape Velocity Foundation, announced at theLongevity Summit Dublin that year.[^levf] Its main programme is the Robust Mouse RejuvenationLongevity Summit Dublin that year.[^levf] Its main programme is the Robust Mouse Rejuvenationseries: rather than testing single compounds, the first study combined four interventions alreadyseries. Rather than testing single compounds, the first study combined four interventions alreadyreported individually to extend mouse lifespan — [[rapamycin]], a senolytic, telomerase genereported individually to extend mouse lifespan ([[rapamycin]], a senolytic, telomerase genetherapy and hematopoietic stem-cell transplantation — starting at eighteen months of age, askingtherapy and hematopoietic stem-cell transplantation), starting at eighteen months of age, to askwhether the effects add.[^lt2022] That design addresses a real gap, since the field has run verywhether the effects add.[^lt2022] The design addresses a real gap, since the field has run veryfew combination studies, and its results, whatever they show, are more checkable than any of hisfew combination studies, and its results, whatever they show, are more checkable than any of hisforecasts.forecasts. His durable influence is that he moved the question. Arguments that aging research was intrinsicallyHis durable influence is on which questions are asked. Arguments that aging research wasdisreputable were common when he began; the [[geroscience-hypothesis]] is now respectable enough tointrinsically disreputable were common when he began; the [[geroscience-hypothesis]] is now respectable enough tobe discussed with regulators, and senolytics, [[epigenetic-reprogramming]] andbe discussed with regulators, and senolytics, [[epigenetic-reprogramming]] and[[aging-biomarkers]] are funded programmes at major institutions. Whether that shift is[[aging-biomarkers]] are funded programmes at major institutions. Whether he caused that shift orattributable to him or merely coincident with him is contested. What is not contested is that themerely coincided with it is contested. It is not contested that the therapies he described in 2005therapies he described in 2005 as achievable within decades remain, twenty years on, unavailable inas achievable within decades remain, twenty years on, unavailable in any clinic.any clinic. ## See also## See also removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
145 lines are the same in both revisions, and 81 of them are not shown. Neither revision here is necessarily the current article — read Aubrey de Grey for the text this wiki stands behind today.